There's some interesting perspectives on the problems Dendreon...

There's some interesting perspectives on the problems Dendreon is facing with gaining market penetration for Provenge in here:

http://www.ft.com/intl/cms/s/2/d9495d4c-d26f-11e0-9137-00144feab49a,dwp_uuid=e8477cc4-c820-11db-b0dc-000b5df10621.html#axzz1WXNZUK7I

Note the comments of practising oncologists - very significant. It is the clinicians who ultimately determine how much of a therapy is used.

Anyone who has been around Prima for a while knows how closely aligned the technology is and also how the market reference PRR responds to significant happenings in Dendreon.

I am sure that MR and Co are watching very carefully the fallout around Dendreon and will be building an approach to marketing cVac which will try to avoid falling into the same traps.

And if that's not enough to motivate them, I'm sure this will:

http://pr-usa.net/index.php?option=com_content&task=view&id=865815&Itemid=34